Testing SRG-514 during breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial studies a drug called SRG-514 that is given during surgery to treat triple-negative breast cancer. It is for people having breast-conserving surgery (lumpectomy) and aims to see if it can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with triple-negative breast cancer (TNBC) at stage II or III.
- You are scheduled to have a lumpectomy (breast-conserving surgery) within 28 days of screening.
- You have not had chemotherapy or other treatments before surgery (no neoadjuvant therapy).
- You do not have inflammatory breast cancer or cancer that has spread to other parts of the body (stage IV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs given before surgery to treat early-stage triple-negative breast cancer that is PD-L1 positive. The goal is to see if the combination can shrink the tumor and improve outcomes.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests a combination of two drugs (Sacituzumab Govitecan and Tislelizumab) given before surgery to shrink early-stage triple-negative breast cancer. The goal is to see if a lower dose of treatment can still work well.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.